Strong sales of drugs, vaccines, propel Merck in 3Q
Drugmaker Merck, bouncing back from a $1.6 billion hit from the coronavirus pandemic in the second quarter, boosted its third-quarter profit by 55% and blew past Wall Street expectations. The strong result was due to sales slightly higher than a year ago, plus restrained spending and a one-time gain.
Become a Subscriber!
You have read all of your free articles this month. Select a plan below to start your subscription today.
Already a subscriber? Login
